Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$13.4 million.

  • Pharmaceuticals' Profit After Tax fell 9203.16% to -$13.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$21.6 million, marking a year-over-year decrease of 14821.23%. This contributed to the annual value of -$39.3 million for FY2024, which is 24950.3% down from last year.
  • Per Pharmaceuticals' latest filing, its Profit After Tax stood at -$13.4 million for Q2 2025, which was down 9203.16% from -$10.8 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Profit After Tax registered a high of $61.2 million during Q4 2022, and its lowest value of -$13.4 million during Q2 2025.
  • Its 4-year average for Profit After Tax is $3.7 million, with a median of -$6.4 million in 2023.
  • As far as peak fluctuations go, Pharmaceuticals' Profit After Tax surged by 26340.25% in 2024, and later crashed by 21282.54% in 2025.
  • Quarter analysis of 4 years shows Pharmaceuticals' Profit After Tax stood at $61.2 million in 2022, then fell by 23.78% to $46.6 million in 2023, then tumbled by 114.94% to -$7.0 million in 2024, then plummeted by 92.03% to -$13.4 million in 2025.
  • Its last three reported values are -$13.4 million in Q2 2025, -$10.8 million for Q1 2025, and -$7.0 million during Q2 2024.